MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-10-2026
Medpace Holdings Interest Expense 2011-2026 | MEDP
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.34 M | 4.06 M | -655 K | 7.07 M | 3.34 M | 1.18 M | -863 K | 1.06 M | -354 K | -423 K | -1.13 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.07 M | -5.34 M | 722 K |
Quarterly Interest Expense Medpace Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -489 K | -2.88 M | -1.82 M | - | -1.02 M | -133 K | 4.59 M | - | -1.6 M | -1.28 M | 687 K | - | 5.65 M | 2.31 M | 1.07 M | - | 1.06 M | 265 K | 924 K | - | 584 K | 239 K | 617 K | - | -273 K | -19 K | -282 K | - | 482 K | 478 K | -153 K | - | -145 K | -125 K | -372 K | - | -378 K | -6 K | -935 K | - | 50 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.65 M | -2.88 M | 229 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.71 | 0.73 % | $ 7.5 M |  USA |
 |
Illumina
ILMN
|
-292 M | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.13 | -2.74 % | $ 4.89 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 104.91 | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Personalis
PSNL
|
24 K | $ 7.61 | 4.82 % | $ 451 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.62 | 2.16 % | $ 276 M | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.88 | 2.81 % | $ 3.94 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 31.72 | -4.52 % | $ 1.61 B | USA |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.6 | 10.34 % | $ 106 M | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 478.12 | 0.79 % | $ 180 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.42 | 0.54 % | $ 22 B | USA |